Ta Hsung Tung

Array ( [id] => 11311739 [patent_doc_number] => 20160347849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'ANTIBODIES AGAINST OX40 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/166114 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 88 [patent_figures_cnt] => 88 [patent_no_of_words] => 102335 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15166114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060791 [patent_doc_number] => 20160257753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'HUMAN CTLA-4 ANTIBODIES AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/163332 [patent_app_country] => US [patent_app_date] => 2016-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 41324 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15163332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13289249 [patent_doc_number] => 10155800 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-18 [patent_title] => CTLA4-Ig immunoadhesins [patent_app_type] => utility [patent_app_number] => 15/159667 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 24474 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15159667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270567 [patent_doc_number] => 20160333114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 15/156159 [patent_app_country] => US [patent_app_date] => 2016-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 42711 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15156159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410345 [patent_doc_number] => 20180256715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => ANTI-CTLA-4 BLOCKADE [patent_app_type] => utility [patent_app_number] => 15/571174 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11122044 [patent_doc_number] => 20160319019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'Anti-PD-1 Antibodies' [patent_app_type] => utility [patent_app_number] => 15/152192 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 20133 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15152192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11047566 [patent_doc_number] => 20160244524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'Combination Immunotherapy for the Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/145780 [patent_app_country] => US [patent_app_date] => 2016-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11188 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15145780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067712 [patent_doc_number] => 20160264675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD' [patent_app_type] => utility [patent_app_number] => 15/142538 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 93998 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15142538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763557 [patent_doc_number] => 10174113 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody [patent_app_type] => utility [patent_app_number] => 15/141769 [patent_app_country] => US [patent_app_date] => 2016-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 18730 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15141769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205845 [patent_doc_number] => 20180051070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders' [patent_app_type] => utility [patent_app_number] => 15/131691 [patent_app_country] => US [patent_app_date] => 2016-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 75 [patent_figures_cnt] => 75 [patent_no_of_words] => 104942 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15131691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107637 [patent_doc_number] => 20160304607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/130513 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 42691 [patent_no_of_claims] => 103 [patent_no_of_ind_claims] => 56 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15130513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11449212 [patent_doc_number] => 09572837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-21 [patent_title] => 'Reducing immune tolerance induced by PD-L1' [patent_app_type] => utility [patent_app_number] => 15/093643 [patent_app_country] => US [patent_app_date] => 2016-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14410 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15093643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11009766 [patent_doc_number] => 20160206719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY' [patent_app_type] => utility [patent_app_number] => 15/091060 [patent_app_country] => US [patent_app_date] => 2016-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 37094 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15091060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703132 [patent_doc_number] => 10953045 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Agents and compositions for eliciting an immune response [patent_app_type] => utility [patent_app_number] => 15/563815 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 33417 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12260618 [patent_doc_number] => 20180079814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'COMBINED ANTI-PLD-1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL LUNG CANCER' [patent_app_type] => utility [patent_app_number] => 15/562247 [patent_app_country] => US [patent_app_date] => 2016-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9692 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 25 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15562247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107641 [patent_doc_number] => 20160304610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'ANTIBODIES TO ICOS' [patent_app_type] => utility [patent_app_number] => 15/076867 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 55303 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15076867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13887809 [patent_doc_number] => 10196445 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-02-05 [patent_title] => Ipilimumab variant with enhanced ADCC [patent_app_type] => utility [patent_app_number] => 15/071489 [patent_app_country] => US [patent_app_date] => 2016-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 12242 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15071489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980023 [patent_doc_number] => 20160176967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'METHODS AND MATERIALS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/054385 [patent_app_country] => US [patent_app_date] => 2016-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6197 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15054385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13139861 [patent_doc_number] => 10087251 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-02 [patent_title] => Amino acid sequences that modulate the interaction between cells of the immune system [patent_app_type] => utility [patent_app_number] => 15/050737 [patent_app_country] => US [patent_app_date] => 2016-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 146098 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15050737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369105 [patent_doc_number] => 10800846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => PD-1/PD-L1 inhibitors for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/553437 [patent_app_country] => US [patent_app_date] => 2016-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 22113 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553437 [rel_patent_id] =>[rel_patent_doc_number] =>)